| Autor: |
Bert Malengier-Devlies, Sebastiaan ter Horst, Kai Dallmeier, Suzanne Kaptein, Li-Hsin Li, Ghislain Opdenakker, Lindsey Bervoets, Johan Neyts, Osbourne Quaye, Lorena Sanchez Felipe, Dominique Van Looveren, Laura Seldeslachts, Sapna Sharma, Xin Zhang, Koen Van Laere, Madina Rasulova, Christopher Cawthorne, Ji Ma, Greetje Vande Velde, Robbert Boudewijns, Lotte Coelmont, Carolien De Keyzer, Birgit Weynand, Hendrik Jan Thibaut, Michael Bright Yakass, Viktor Lemmens, Niraj Mishra, Dirk E. Teuwen, Laurens Liesenborghs, Sander Jansen, Mahadesh Prasad Arkalagud Javarappa, Patrick Matthys, Thomas Vercruysse |
| Rok vydání: |
2020 |
| Předmět: |
|
| DOI: |
10.1101/2020.07.08.193045 |
| Popis: |
The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-191. We employed the live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express the prefusion form of the SARS-CoV-2 Spike antigen. In mice, the vaccine candidate, tentatively named YF-S0, induces high levels of SARS-CoV-2 neutralizing antibodies and a favorable Th1 cell-mediated immune response. In a stringent hamster SARS-CoV-2 challenge model2, vaccine candidate YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose confers protection from lung disease in most vaccinated animals even within 10 days. These results warrant further development of YF-S0 as a potent SARS-CoV-2 vaccine candidate. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
